Don S. Dizon, MD, of the Lifespan Cancer Institute, and Richard T. Penson, MD, of Massachusetts General Hospital Cancer Center, discuss phase III study findings on the PARP inhibitor olaparib, which showed a significantly higher objective response rate vs nonplatinum chemotherapy for patients with ovarian cancer who relapsed, are platinum-sensitive, and have BRCA-mutant disease (Abstract 5506).
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, discuss the Australian and ...
Kamran A. Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, reports on a trial in progress that is investigating whether treatment with atezolizumab plus...
Alok A. Khorana, MD, of the Cleveland Clinic, and Hedy L. Kindler, MD, of The University of Chicago, discuss phase III findings on olaparib as maintenance treatment following first...
Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses long-term survival data on patients with advanced non–smal...
Thomas J. George, MD, of NRG Oncology and The University of Florida Health Cancer Center, discusses the initial phase II results from a clinical trial using total neoadjuvant...